Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 90 articles: HTML format Text format

Single Articles

June 2018
1. PATEL JD, Chmura SJ
   Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
   Cancer. 2018 Jun 15. doi: 10.1002/cncr.31557.
   PubMed     Text format    
   
   
   May 2018
2. GOLDWASSER F, Vinant P, Aubry R, Rochigneux P, et al
   Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.
   Cancer. 2018 May 9. doi: 10.1002/cncr.31536.
   PubMed     Text format     Abstract available
   
   
   April 2018
3. SPIGEL DR, Burris HA 3rd, Greco FA, Shih KC, et al
   Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
   Cancer. 2018 Apr 12. doi: 10.1002/cncr.31290.
   PubMed     Text format     Abstract available
   
   
   
4. ARBOUR KC, Riely GJ
   Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
   Cancer. 2018 Apr 12. doi: 10.1002/cncr.31289.
   PubMed     Text format    
   
   
   
5. PRINTZ C
   Lung cancer screening based on personal risk may save more lives.
   Cancer. 2018;124:1315.
   PubMed     Text format    
   
   
   March 2018
6. HIRSCH FR, Sequist LV, Gore I, Mooradian M, et al
   Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
   Cancer. 2018 Mar 26. doi: 10.1002/cncr.31313.
   PubMed     Text format     Abstract available
   
   
   February 2018
7. SPIGEL DR, Hainsworth JD, Joseph MJ, Shipley DL, et al
   Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
   Cancer. 2018 Feb 16. doi: 10.1002/cncr.30986.
   PubMed     Text format     Abstract available
   
   
   January 2018
8. CASSIDY RJ, Zhang X, Switchenko JM, Patel PR, et al
   Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
   Cancer. 2018 Jan 8. doi: 10.1002/cncr.31077.
   PubMed     Text format     Abstract available
   
   
   December 2017
9. TANDBERG DJ, Tong BC, Ackerson BG, Kelsey CR, et al
   Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.
   Cancer. 2017 Dec 19. doi: 10.1002/cncr.31196.
   PubMed     Text format     Abstract available
   
   
   
10. RICHARDS TB, Henley SJ, Puckett MC, Weir HK, et al
    Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5079-5099.
    PubMed     Text format     Abstract available
    
    
    
11. ASSI HI, Kamphorst AO, Moukalled NM, Ramalingam SS, et al
    Immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31105.
    PubMed     Text format     Abstract available
    
    
    
12. KATAKAMI N, Uchino J, Yokoyama T, Naito T, et al
    Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
    Cancer. 2017 Dec 4. doi: 10.1002/cncr.31128.
    PubMed     Text format     Abstract available
    
    
    
13. NIXON NA, Khan OF, Imam H, Tang PA, et al
    Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
    Cancer. 2017;123:4672-4679.
    PubMed     Text format     Abstract available
    
    
    
14. MANSOUR MSI, Seidal T, Mager U, Baigi A, et al
    Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Cancer. 2017;125:908-917.
    PubMed     Text format     Abstract available
    
    
    November 2017
15. HAHN EJ, Rayens MK, Wiggins AT, Gan W, et al
    Lung cancer incidence and the strength of municipal smoke-free ordinances.
    Cancer. 2017 Nov 28. doi: 10.1002/cncr.31142.
    PubMed     Text format     Abstract available
    
    
    
16. SPIEGEL ML, Goldman JW, Wolf BR, Nameth DJ, et al
    Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.
    Cancer. 2017 Nov 10. doi: 10.1002/cncr.31056.
    PubMed     Text format     Abstract available
    
    
    October 2017
17. STOY SP, Rosen L, Mueller J, Murgu S, et al
    Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.
    Cancer. 2017 Oct 20. doi: 10.1002/cncy.21941.
    PubMed     Text format     Abstract available
    
    
    
18. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available
    
    
    
19. HEYMANN JJ, Bulman WA, Swinarski D, Pagan CA, et al
    Programmed death-ligand 1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Cancer. 2017 Oct 12. doi: 10.1002/cncy.21937.
    PubMed     Text format     Abstract available
    
    
    
20. SULLIVAN DR, Ganzini L, Lapidus JA, Hansen L, et al
    Improvements in hospice utilization among patients with advanced-stage lung cancer in an integrated health care system.
    Cancer. 2017 Oct 10. doi: 10.1002/cncr.31047.
    PubMed     Text format     Abstract available
    
    
    
21. CASSIDY RJ, Zhang X, Patel PR, Shelton JW, et al
    Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cancer. 2017;123:3681-3690.
    PubMed     Text format     Abstract available
    
    
    September 2017
22. PILLAI RN, Behera M, Owonikoko TK, Kamphorst AO, et al
    Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31043.
    PubMed     Text format     Abstract available
    
    
    
23. ARBOUR KC, Kris MG, Riely GJ, Ni A, et al
    Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30990.
    PubMed     Text format     Abstract available
    
    
    
24. YANG D, Zhang X, Powell CA, Ni J, et al
    Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study.
    Cancer. 2017 Sep 20. doi: 10.1002/cncr.31020.
    PubMed     Text format     Abstract available
    
    
    
25. LAMBROS L, Guibourg B, Uguen A
    Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France.
    Cancer. 2017 Sep 11. doi: 10.1002/cncy.21919.
    PubMed     Text format    
    
    
    
26. TRONCONE G
    Reply to Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France.
    Cancer. 2017 Sep 11. doi: 10.1002/cncy.21918.
    PubMed     Text format    
    
    
    
27. PRINTZ C
    Nivolumab improves survival for patients with advanced lung cancer.
    Cancer. 2017;123:3211.
    PubMed     Text format    
    
    
    
28. SADETZKI S, Chetrit A, Freedman LS, Hakak N, et al
    Cancer risk among Holocaust survivors in Israel-A nationwide study.
    Cancer. 2017;123:3335-3345.
    PubMed     Text format     Abstract available
    
    
    August 2017
29. MOORE KN, Borghaei H, O'Malley DM, Jeong W, et al
    Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors.
    Cancer. 2017;123:3080-3087.
    PubMed     Text format     Abstract available
    
    
    
30. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available
    
    
    
31. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available
    
    
    
32. HUNG YP, Lovitch SB, Qian X
    Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.
    Cancer. 2017;125:604-614.
    PubMed     Text format     Abstract available
    
    
    
33. CAPPELLESSO R, Galasso M, Nicole L, Dabrilli P, et al
    miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cancer. 2017;125:635-643.
    PubMed     Text format     Abstract available
    
    
    July 2017
34. PISAPIA P, Lozano MD, Vigliar E, Bellevicine C, et al
    ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Cancer. 2017 Jul 25. doi: 10.1002/cncy.21899.
    PubMed     Text format     Abstract available
    
    
    
35. PILLAI RN, Behera M, Berry LD, Rossi MR, et al
    HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30869.
    PubMed     Text format     Abstract available
    
    
    
36. RWIGEMA JM, Verma V, Lin L, Berman AT, et al
    Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30870.
    PubMed     Text format     Abstract available
    
    
    June 2017
37. GOLDSTEIN DA, Bilal U, Prasad V
    Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30868.
    PubMed     Text format    
    
    
    
38. GAINOR JF
    Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
    Cancer. 2017 Jun 16. doi: 10.1002/cncy.21882.
    PubMed     Text format    
    
    
    
39. PRINTZ C
    Lung cancer screening rates remain very low among current and former smokers.
    Cancer. 2017;123:2189.
    PubMed     Text format    
    
    
    
40. LILO MT, Allison DB, Younes BK, Cui M, et al
    The critical role of EBUS-TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings.
    Cancer. 2017 Jun 13. doi: 10.1002/cncy.21886.
    PubMed     Text format     Abstract available
    
    
    
41. ZAKOWSKI MF
    Analytic inquiry: Molecular testing in lung cancer.
    Cancer. 2017;125.
    PubMed     Text format     Abstract available
    
    
    
42. BAUM JE, Zhang P, Hoda RS, Geraghty B, et al
    Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Cancer. 2017;125:398-406.
    PubMed     Text format     Abstract available
    
    
    May 2017
43. KEATING JJ, Runge JJ, Singhal S, Nims S, et al
    Intraoperative near-infrared fluorescence imaging targeting folate receptors identifies lung cancer in a large-animal model.
    Cancer. 2017;123:1051-1060.
    PubMed     Text format     Abstract available
    
    
    
44. MINO-KENUDSON M
    Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.
    Cancer. 2017 May 4. doi: 10.1002/cncy.21873.
    PubMed     Text format    
    
    
    
45. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    PubMed     Text format     Abstract available
    
    
    
46. CHUANG JC, Neal JW
    The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30718.
    PubMed     Text format    
    
    
    April 2017
47. ERSEK M, Miller SC, Wagner TH, Thorpe JM, et al
    Association between aggressive care and bereaved families' evaluation of end-of-life care for veterans with non-small cell lung cancer who died in Veterans Affairs facilities.
    Cancer. 2017 Apr 17. doi: 10.1002/cncr.30700.
    PubMed     Text format     Abstract available
    
    
    
48. SABRA MM, Sherman EJ, Tuttle RM
    Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30690.
    PubMed     Text format     Abstract available
    
    
    March 2017
49. ZHANG L, Jiang T, Li X, Wang Y, et al
    Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30677.
    PubMed     Text format     Abstract available
    
    
    
50. SUN B, Brooks ED, Komaki RU, Liao Z, et al
    7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30693.
    PubMed     Text format     Abstract available
    
    
    
51. KEAM B, Kim MK, Choi Y, Choi SJ, et al
    Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.
    Cancer. 2017;123:841-848.
    PubMed     Text format     Abstract available
    
    
    February 2017
52. VERMA V, Shostrom VK, Kumar SS, Zhen W, et al
    Multi-institutional experience of stereotactic body radiotherapy for large (>/=5 centimeters) non-small cell lung tumors.
    Cancer. 2017;123:688-696.
    PubMed     Text format     Abstract available
    
    
    
53. SAAB J, Hoda RS, Narula N, Hoda SA, et al
    Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens.
    Cancer. 2017;125:128-137.
    PubMed     Text format     Abstract available
    
    
    
54. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    PubMed     Text format     Abstract available
    
    
    January 2017
55. REYNOLDS JP, Zhou Y, Jakubowski MA, Wang Z, et al
    Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
    Cancer. 2017 Jan 13. doi: 10.1002/cncy.21812.
    PubMed     Text format     Abstract available
    
    
    
56. PRINTZ C
    FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer.
    Cancer. 2017;123:191.
    PubMed     Text format    
    
    
    
57. VELIZHEVA NP, Rechsteiner MP, Wong CE, Zhong Q, et al
    Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Cancer. 2017;125:30-40.
    PubMed     Text format     Abstract available
    
    
    December 2016
58. BISHOP JA, French CA, Ali SZ
    Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.
    Cancer. 2016;124:901-908.
    PubMed     Text format     Abstract available
    
    
    September 2016
59. SANBORN RE, Patel JD, Masters GA, Jayaram N, et al
    A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
    Cancer. 2016 Sep 1. doi: 10.1002/cncr.30287.
    PubMed     Text format     Abstract available
    
    
    August 2016
60. LAMPSON BL, Nishino M, Dahlberg SE, Paul D, et al
    Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
    Cancer. 2016 Aug 15. doi: 10.1002/cncr.30270.
    PubMed     Text format     Abstract available
    
    
    July 2016
61. PETERS EN, Warren GW, Sloan JA, Marshall JR, et al
    Tobacco assessment in completed lung cancer treatment trials.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30223.
    PubMed     Text format    
    
    
    
62. MILLER JA, Kotecha R, Suh JH
    Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30188.
    PubMed     Text format    
    
    
    
63. HALASZ LM, Uno H, Punglia RS
    Reply to comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30187.
    PubMed     Text format    
    
    
    June 2016
64. LIM SH, Sun JM, Choi YL, Kim HR, et al
    Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30135.
    PubMed     Text format     Abstract available
    
    
    
65. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    PubMed     Text format     Abstract available
    
    
    
66. ERSEK JL, Eberth JM, McDonnell KK, Strayer SM, et al
    Knowledge of, attitudes toward, and use of low-dose computed tomography for lung cancer screening among family physicians.
    Cancer. 2016 Jun 13. doi: 10.1002/cncr.29944.
    PubMed     Text format     Abstract available
    
    
    May 2016
67. BELANI CP, Dahlberg SE, Rudin CM, Fleisher M, et al
    Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
    Cancer. 2016 May 10. doi: 10.1002/cncr.30062.
    PubMed     Text format     Abstract available
    
    
    April 2016
68. HALASZ LM, Uno H, Hughes M, D'Amico T, et al
    Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Apr 18. doi: 10.1002/cncr.30009.
    PubMed     Text format     Abstract available
    
    
    
69. GONCALVES PH, Peterson SL, Vigneau FD, Shore RD, et al
    Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data.
    Cancer. 2016 Apr 8. doi: 10.1002/cncr.30000.
    PubMed     Text format     Abstract available
    
    
    March 2016
70. OU W, Li N, Wang SY, Li J, et al
    Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
    Cancer. 2016;122:740-7.
    PubMed     Text format     Abstract available
    
    
    
71. MOR V, Joyce NR, Cote DL, Gidwani RA, et al
    The rise of concurrent care for veterans with advanced cancer at the end of life.
    Cancer. 2016;122:782-90.
    PubMed     Text format     Abstract available
    
    
    February 2016
72. ARMSTRONG K, Kim JJ, Halm EA, Ballard RM, et al
    Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs.
    Cancer. 2016 Feb 29. doi: 10.1002/cncr.29937.
    PubMed     Text format     Abstract available
    
    
    
73. FUCITO LM, Czabafy S, Hendricks PS, Kotsen C, et al
    Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco.
    Cancer. 2016 Feb 24. doi: 10.1002/cncr.29926.
    PubMed     Text format     Abstract available
    
    
    
74. GUIJARRO-MUNOZ I, Roarty EB, Heymach JV
    Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29894.
    PubMed     Text format    
    
    
    
75. TAKEDA M, Yamanaka T, Seto T, Hayashi H, et al
    Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29893.
    PubMed     Text format     Abstract available
    
    
    
76. TEVAARWERK AJ, Lee JW, Terhaar A, Sesto ME, et al
    Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.
    Cancer. 2016;122:438-46.
    PubMed     Text format     Abstract available
    
    
    January 2016
77. LITZELMAN K, Kent EE, Rowland JH
    Social factors in informal cancer caregivers: The interrelationships among social stressors, relationship quality, and family functioning in the CanCORS data set.
    Cancer. 2016;122:278-86.
    PubMed     Text format     Abstract available
    
    
    
78. 
    Xiu-Yi Zhi, Jin-Ming Yu, and Yuan-Kai Shi. Chinese Guidelines on the Diagnosis and Treatment of Primary Lung Cancer (2015 Version). Cancer. 2015;121:3165-3181.
    Cancer. 2016;122:162.
    PubMed     Text format    
    
    
    December 2015
79. VILLALONA-CALERO MA, Lam E, Otterson GA, Zhao W, et al
    Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
    Cancer. 2015 Dec 28. doi: 10.1002/cncr.29856.
    PubMed     Text format     Abstract available
    
    
    
80. BUNN PA JR, Gaspar LE, Weyant MJ, Mitchell JD, et al
    Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer.
    Cancer. 2015 Dec 23. doi: 10.1002/cncr.29797.
    PubMed     Text format    
    
    
    
81. STEUER CE, Behera M, Berry L, Kim S, et al
    Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Cancer. 2015 Dec 22. doi: 10.1002/cncr.29812.
    PubMed     Text format     Abstract available
    
    
    November 2015
82. GREM JL, Kos ME, Evande RE, Meza JL, et al
    A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Cancer. 2015;121:3862-8.
    PubMed     Text format     Abstract available
    
    
    
83. TRAEGER L, McDonnell TM, McCarty CE, Greer JA, et al
    Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial.
    Cancer. 2015;121:3905-13.
    PubMed     Text format     Abstract available
    
    
    September 2015
84. NAIDOO J, Sima CS, Rodriguez K, Busby N, et al
    Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
    Cancer. 2015;121:3212-20.
    PubMed     Text format     Abstract available
    
    
    
85. BISHOP AJ, Ensor J, Moulder SL, Shaitelman SF, et al
    Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.
    Cancer. 2015 Sep 8. doi: 10.1002/cncr.29681.
    PubMed     Text format     Abstract available
    
    
    
86. MAIN BG, McNair AG, Blazeby JM
    Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Sep 3. doi: 10.1002/cncr.29673.
    PubMed     Text format    
    
    
    
87. WINNER M, Kim Y, Pawlik TM
    Reply to patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Sep 3. doi: 10.1002/cncr.29671.
    PubMed     Text format    
    
    
    
88. CHEN ZM, Peto R, Iona A, Guo Y, et al
    Emerging tobacco-related cancer risks in China: A nationwide, prospective study of 0.5 million adults.
    Cancer. 2015;121 Suppl 17:3097-106.
    PubMed     Text format     Abstract available
    
    
    
89. PASKETT ED, Bernardo BM, Khuri FR
    Tobacco and China: The worst is yet to come.
    Cancer. 2015;121 Suppl 17:3052-4.
    PubMed     Text format    
    
    
    June 2015
90. KIM Y, Winner M, Page A, Tisnado DM, et al
    Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Jun 19. doi: 10.1002/cncr.29530.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: